Anna Malczewska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7334561/publications.pdf

Version: 2024-02-01

471509 526287 34 766 17 27 citations h-index g-index papers 34 34 34 787 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The NETest. Endocrinology and Metabolism Clinics of North America, 2018, 47, 485-504.	3.2	91
2	PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 895-906.	6.4	73
3	Surgical Management of Patients with Neuroendocrine Neoplasms of the Appendix: Appendectomy or More. Neuroendocrinology, 2018, 106, 242-251.	2.5	70
4	A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 2018, 107, 73-90.	2.5	61
5	MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocrine-Related Cancer, 2016, 23, 711-726.	3.1	54
6	The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Advances in Medical Sciences, 2020, 65, 18-29.	2.1	38
7	The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progressionâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 631-639.	1.4	35
8	Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve followâ€up after curative surgical resection of wellâ€differentiated pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 2018, 118, 37-48.	1.7	30
9	Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 867-872.	3.6	29
10	An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis. Neuroendocrinology, 2020, 110, 198-216.	2.5	28
11	NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease. Neuroendocrinology, 2019, 108, 219-231.	2.5	27
12	NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocrine Connections, 2019, 8, 442-453.	1.9	27
13	Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocrine Connections, 2017, 6, 71-81.	1.9	25
14	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Annals of Surgical Oncology, 2021, 28, 7506-7517.	1.5	25
15	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Annals of Surgery, 2021, 274, 481-490.	4.2	22
16	Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors. Annals of Surgery, 2021, 274, e1-e9.	4.2	20
17	Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience. Neuroendocrinology, 2021, 111, 304-319.	2.5	18
18	Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS ONE, 2019, 14, e0218592.	2.5	17

#	Article	IF	CITATIONS
19	NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocrine Connections, 2021, 10, 110-123.	1.9	17
20	Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Neuroendocrinology, 2020, 110, 185-197.	2.5	14
21	Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus. Journal of Nuclear Medicine, 2019, 60, 7-8.	5.0	10
22	The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual disease. BMC Gastroenterology, 2020, 20, 235.	2.0	8
23	Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection. Endocrine, 2020, 69, 430-440.	2.3	7
24	Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy. European Journal of Cardio-thoracic Surgery, 2020, 57, 1195-1202.	1.4	6
25	Nutritional status at the moment of diagnosis in childhood cancer patients. Pediatric Endocrinology, Diabetes and Metabolism, 2017, 23, 77-82.	0.7	6
26	Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: "The times they are a changinâ€. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 243-253.	1.4	4
27	A 13-gene colorectal cancer liquid biopsy with greater than 90 percent accuracy in diagnosis and assessment of disease status Journal of Clinical Oncology, 2020, 38, 18-18.	1.6	3
28	A blood-based multi-mRNA liquid biopsy with >90% accuracy for diagnosis and assessment of prostate cancers Journal of Clinical Oncology, 2020, 38, 5574-5574.	1.6	1
29	A genomic blood test (NETest) identifies neuroendocrine transformation of prostate cancer Journal of Clinical Oncology, 2020, 38, e17511-e17511.	1.6	0
30	A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status Journal of Clinical Oncology, 2020, 38, e16079-e16079.	1.6	0
31	The utility of blood-based molecular tools-the NETest-to monitor and evaluate the efficacy of PRRT in neuroendocrine tumors Journal of Clinical Oncology, 2020, 38, 3568-3568.	1.6	0
32	Inefficacy of chromogranin a assays as neuroendocrine tumor diagnostic tools compared to the NETest Journal of Clinical Oncology, 2020, 38, 4612-4612.	1.6	0
33	PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest Journal of Clinical Oncology, 2020, 38, 625-625.	1.6	0
34	ENETS single center of excellence experience with the NETest: A real-world assessment of 565 patients Journal of Clinical Oncology, 2020, 38, 605-605.	1.6	0